Turmerones

Other Names

(6S)-2-Methyl-6-(4-methylphenyl)-2-hepten-4-one(6S)-2-methyl-6-(4-methylphenyl)hept-2-en-4-one(R)-ar-Turmerone(S)-2-Methyl-6-(4-methylphenyl)-2-hepten-4-one(S)-2-Methyl-6-(p-tolyl)hept-2-en-4-one(S)-ar-Turmerone2-Hepten-4-one, 2-methyl-6-(4-methyl-2,4-cyclohexadien-1-yl)-2-Hepten-4-one, 2-methyl-6-(4-methylene-2-cyclohexen-1-yl)-2-Hepten-4-one, 2-methyl-6-(4-methylphenyl)-2-Hepten-4-one, 2-methyl-6-(4-methylphenyl)-, (6S)-2-Hepten-4-one, 2-methyl-6-(4-methylphenyl)-, (S)-2-Hepten-4-one, 2-methyl-6-p-tolyl-2-Hepten-4-one, 2-methyl-6-[(1S)-4-methylene-2-cyclohexen-1-yl]-, (6S)-2-Methyl-6-(4-methyl-2,4-cyclohexadien-1-yl)-2-hepten-4-one2-methyl-6-(4-methylcyclohexa-2,4-dien-1-yl)hept-2-en-4-one2-Methyl-6-(4-methylphenyl)-2-hepten-4-one2-methyl-6-(4-methylphenyl)hept-2-en-4-one2-methyl-6-(p-tolyl)hept-2-en-4-one2-Methyl-6-p-tolyl-2-hepten-4-one2-Methyl-6-p-tolylhept-2-en-4-onealpha-turmeronear-Tumeronear-turmeroneAromatic turmeronebeta-turmeroneCurloneturmeroneTurmerone (-ar)α-turmeroneβ-turmerone

Synopsis

Turmerones: A Comprehensive Reference

1. Identity, Nomenclature, and Natural Sources

Turmerones are a group of related chemical compounds of the sesquiterpene class. They are found in turmeric (Curcuma longa), from which they derive their name, as well as other related plants such as Curcuma caesia. Curcuma longa L. is a perennial rhizomatous herbaceous plant in the Zingiberaceae family, native to South Asia. Turmeric is a rhizomatous plant native to Southeast Asia, but is extensively cultivated worldwide, particularly in tropical countries including India, Pakistan, Bangladesh, China, Taiwan, Thailand, Sri Lanka, Indonesia, northern Australia, Costa Rica, Haiti, Jamaica, Peru, and Brazil.

There are multiple structural types of turmerones which differ in the number and placement of double bonds, including α-turmerone, β-turmerone (also known as curlone), and ar-turmerone. Each of these types consists of multiple stereoisomers. Ar-turmerone, α-turmerone, and β-turmerone are the principal bisabolane sesquiterpenes within the essential oil of the turmeric rhizome. The aromatic (ar-) designation in ar-turmerone refers to the presence of an aromatic ring within its chemical structure, distinguishing it from the non-aromatic α- and β-forms.

The aroma of turmeric spice is principally derived from α- and β-turmerones and aromatic turmerone (ar-turmerone). Turmeric rhizome oil is responsible for this spice's characteristic taste and smell; dried rhizomes contain about 3–6% essential oil, which is extracted from powdered turmeric rhizomes through steam distillation. Within the essential oil, the major components are α-turmerone (12.6–44.5%), β-turmerone (9.1–37.8%), ar-turmerone (12.2–36.6%), β-sesquiphellandrene (5.0–14.6%), α-zingiberene (5.0–12.8%), germacrone (10.3–11.1%), terpinolene (10.0–10.2%), ar-curcumene (5.5–9.8%), and α-phellandrene (5.0–6.7%).

Ar-turmerone, α-turmerone, and β-turmerone are utilized for the quality control of C. longa oleoresin and essential oil products. Turmeric's chemical composition is constituted by the presence of turmeric oil, rich in oxygenated sesquiterpenoids (ar-, α-, β-turmerone, and α-atlantone), and curcuminoids (curcumin, monodemethoxycurcumin, and bisdemethoxycurcumin).

Growing conditions such as water availability, sun exposure, and harvest time affect rhizome quality and the essential oil derived from it; for instance, shade-grown turmeric has been reported to yield a 16% increase in the relative abundance of ar-turmerone in the essential oil compared to turmeric grown in full sun.

2. Common Forms and Preparations

Turmerones, as components of turmeric essential oil, occur in several commercially relevant forms:

Turmeric essential oil (steam-distilled): Dried rhizomes contain about 3–6% essential oil, which is extracted from powdered turmeric rhizomes through steam distillation. Authenticated oils are primarily composed of turmerones.
Turmeric oleoresin: Two active components of turmeric are the volatile oil and curcuminoids, and both are present in oleoresin extracted from the turmeric root. Oleoresin preparations thus co-deliver both turmerones and curcuminoids in the ratios found in the native plant.
Whole-root turmeric preparations: Dried powder preparations of turmeric rhizome inherently contain turmerones alongside curcuminoids.
Isolated/purified fractions: A high-speed counter-current chromatography (HSCCC) method has been developed for the preparative separation of four major sesquiterpenoids with similar structures — ar-turmerone, β-turmerone, α-turmerone, and E-α-atlantone — from the essential oil of Curcuma longa, using a two-phase solvent system composed of n-heptane–ethyl acetate–acetonitrile–water; from a single run, over 98% purity of each compound was achievable by HPLC.
Inhaled (aromatherapy) forms: Volatility is a characteristic property of turmerones, and they can be incorporated in the body via inhalation. Inhaled turmerones have been shown to be incorporated in the organs via pathways different from oral administration and can affect the weight gain of mice.

In Europe, turmeric and its essential oil have been listed among botanicals allowed to be used in food supplements; turmeric and curcumin are also listed by the FDA among the generally recognized as safe (GRAS) substances for use as a dye and flavoring in food; and a monograph of turmeric is also included in the European Pharmacopoeia (Curcuma longa rhizome).

Regarding commercial quality, most market samples exhibit the large dominance of turmerones, but some show compositional variability, dilution, or adulteration, including 4/25 samples containing adulteration markers, highlighting the need for production standards.

3. Traditional and Historical Use

Turmeric, either fresh or in dried form, has a long history of medicinal use dating back 4,000 years. Turmeric has been utilized by humans for nearly 6,000 years.

Turmeric has a long history of traditional use in the Chinese and Ayurvedic systems of medicine, particularly as an anti-inflammatory agent, and for the treatment of biliary disorders, anorexia, coryza, cough, diabetic wounds, hepatic disorders, rheumatism, and sinusitis. The powdered rhizome is used externally as an antiseptic and taken internally to cure gastritis.

Traditionally, turmeric has been widely used in Ayurveda medicine and traditional Asian medicine such as traditional Chinese medicine, for treatment of digestive, respiratory, and circulatory diseases, as well as skin diseases. The essential oil fraction of turmeric — and by extension turmerones — was valued within these traditional systems for its distinctive fragrance and for its role in carminative and antifungal preparations. Medicinal uses of the rhizomes arise from volatile oil as a carminative and antifungal, and yellow curcuminoids for antioxidative and anti-inflammatory properties.

Traditional Thai medicine specifically recognized the antifungal properties of the volatile components of turmeric: historically, Thai traditional medicines containing Curcuma longa have been used for the treatment of dermatophytes, with the dry powdered rhizome mixed with a small volume of water and the mixture applied onto infected skin. Turmeric has been used for the treatment of skin diseases, rash, itching, tinea, and ringworm.

It is important to note that while traditional use is well-documented for whole turmeric (including its essential oil), historical texts did not isolate turmerones as a distinct therapeutic entity. The traditional benefits attributed to turmeric as a whole plant preparation encompass the combined action of both curcuminoids and the volatile oil fraction (which includes turmerones), and scientific separation of their individual contributions is a modern undertaking.

4. Key Constituents and Chemical Identity

4.1 Structural Classification

Turmeronoids — namely ar-, α-, and β-turmerone — are the volatile bisabolane sesquiterpenes that may give an important contribution to the plethora of pharmacological activities attributed to turmeric. The major turmeric oil constituents are sesquiterpenes: bisabolanes, guaianes, germacranes, caranes, elemanes, spironolactones, selinanes, santalanes, and caryophyllanes.

Each individual turmerone has a distinct molecular profile:

α-Turmerone: A non-aromatic bisabolane sesquiterpene with a single conjugated enone system. It is among the most abundant of the three principal turmerones in the essential oil.
β-Turmerone (curlone): Also known as curlone, this is a structural isomer of α-turmerone differing in double bond placement.
Ar-turmerone: Contains a phenyl (aromatic) ring, giving it distinct lipophilic and pharmacological properties compared to its aliphatic analogs. Ar-turmerone is an orally active and major bioactive compound of the herb Curcuma longa with anti-tumorigenesis and anti-inflammatory activities.

Turmerone, the lipophilic anti-inflammatory principle of turmeric, can be resolved into its individual bisabolane constituents (ar-, α-, and β-turmerones); comparative evaluation of these compounds against a series of anti-inflammatory targets (NF-κB, STAT3, Nrf2, HIF-1α) has evidenced surprising differences, providing a possible explanation for the contrasting data on the activity of turmeric oil.

4.2 Co-occurring Compounds

Since its discovery, at least 235 phytochemicals, mostly terpenoids and phenolic molecules, have been identified from C. longa, including more than 100 sesquiterpenes, 68 monoterpenes, 22 diarylheptanoids, 5 diterpenes, 3 triterpenoids, 4 sterols, 2 alkaloids, 8 phenylpropene and other phenolic molecules, and 14 other compounds. Most pharmacological properties such as anti-inflammatory and antioxidant ones are attributed to curcumin, whose concentration in the rhizomes ranges from 3 to 9%. However, curcumin-free extracts and preparations have also been reported biologically active on different diseases such as tumors and diabetes.

5. Mechanisms of Action

5.1 Anti-inflammatory Signaling

While the anti-inflammatory properties of turmeric have traditionally been attributed to curcumin, bisabolene sesquiterpenes have emerged as a significant class of anti-inflammatory agents.

The most extensively studied anti-inflammatory mechanisms are those of ar-turmerone. Evidence from in vitro and in vivo models demonstrates that ar-turmerone suppresses Toll-like receptor 4 (TLR4)-dependent NF-κB and MAPK signaling, thereby reducing microglial activation, nitric oxide synthase (iNOS), cyclooxygenase-2 (COX-2), and proinflammatory cytokines (TNF-α, IL-1β, IL-6).

In amyloid-β-stimulated BV2 microglial cells (an in vitro model relevant to neuroinflammation): Ar-turmerone significantly suppressed Aβ-induced expression and activation of MMP-9, iNOS, and COX-2; reduced TNF-α, IL-1β, IL-6, and MCP-1 production; markedly inhibited ROS production; impaired translocation and activation of NF-κB; and inhibited the phosphorylation and degradation of IκB-α as well as the phosphorylation of JNK and p38 MAPK — suggesting that ar-turmerone impairs the Aβ-induced inflammatory response by blocking NF-κB, JNK, and p38 MAPK signaling pathways.

In LPS-stimulated BV-2 microglial cells: increased proinflammatory cytokines and chemokines, PGE₂, NO, ROS production, and MMP-9 enzymatic activity were inhibited by ar-turmerone; mechanistic studies revealed inhibition of LPS-induced JNK, p38 MAPK, and NF-κB activation; ar-turmerone also decreased phosphorylation of STAT-1 and increased phosphorylation of STAT-3 (an anti-inflammatory transcription factor); and ar-turmerone-induced HO-1 and Nrf-2 activation suppressed the activation of neuroinflammatory molecules.

For immune/skin inflammation, ar-turmerone showed inhibition of the transfer of CD8+ T cells in epidermis, and reduced expression of NF-κB and COX-2 as well as phosphorylation of p38 MAPK; it also decreased TNF-α and IL-6 levels and down-regulated IL-17, IL-22, and IL-23 mRNA synthesis. Additionally, ar-turmerone effectively inhibits critical inflammatory cytokines including IFN-γ and IL-2 in CD4+ T cells without adversely affecting their proliferation rates upon stimulation.

An additional mechanism involves the endocannabinoid system: turmeric oleoresin (which contains turmerones) was confirmed as a cannabinoid receptor 2 (CBR2) agonist; it significantly reduced ROS production, downregulated pro-inflammatory cytokines (IL-6, COX-2, metalloproteases), and suppressed signaling pathways such as NFKB1, ERK 1/2, and c-Myc; these effects were reversed upon CBR2 inhibition; and turmeric oleoresin also enhanced HMOX-1 expression and modulated endocannabinoid-related enzymes.

5.2 Modulation of Curcumin Bioavailability (P-glycoprotein Inhibition)

One mechanistically significant role of turmerones is their ability to enhance the intestinal absorption of curcumin. Research hypothesized that the presence of lipophilic components (e.g., turmerones) in turmeric extract would affect the absorption of curcumin; the effects of turmerones on curcumin transport were evaluated in human intestinal epithelial Caco-2 cells, and the roles of turmerones on P-glycoprotein (P-gp) activities and mRNA expression were also evaluated. Results showed that in the presence of α- and aromatic turmerones, the amount of curcumin transported into the Caco-2 cells in 2 hours was significantly increased. α-Turmerone and verapamil (a P-gp inhibitor) significantly inhibited the efflux of rhodamine-123 and digoxin, i.e., inhibited the activity of P-gp.

Co-administration of turmerones, the sesquiterpenes occurring in turmeric's essential oil, may enhance the bioavailability of curcumin. This mechanism may partly explain why whole-turmeric preparations show greater biological activity than equivalent doses of isolated curcumin.

5.3 Antioxidant Mechanisms

Volatile oils in turmeric, including turmerones, exhibit antimicrobial, anti-inflammatory, and antioxidant properties, contributing to turmeric's broad spectrum of biological activities. In vitro tests found that oil extracted from Curcuma longa rhizomes was able to sequester hydroxyl radicals (IC₅₀ = 200 μg/mL) and superoxide anions (IC₅₀ = 135 μg/mL) and inhibited lipid peroxidation (IC₅₀ = 400 μg/mL). In vivo tests with mice found that oral administration of 500 mg/kg increased levels of the antioxidant enzymes superoxide dismutase, glutathione reductase, and glutathione-S-transferase.

5.4 Neuroprotective Mechanisms

In cell and animal models, turmerones stimulate neural stem cell differentiation and proliferation, promote neurite outgrowth, prevent deprivation-induced apoptosis, inhibit acetylcholinesterase activity, and protect against glutamate- or amyloid-β-induced toxicity. Brain concentration analysis confirmed the ability of ar-turmerone to cross the blood–brain barrier and persist in brain tissue for up to 24 h following intraperitoneal administration.

Regarding Alzheimer's disease-related mechanisms: biochemical analyses of hippocampal tissues in animal models revealed reduced TLR4 expression and NF-κB activation, decreased acetylcholinesterase (AChE) activity, and restoration of acetylcholine (ACh) levels following ar-turmerone treatment, suggesting neuroprotective effects by inhibiting TLR4/NF-κB-mediated neuroinflammation and preserving cholinergic function.

Regarding Parkinson's disease-related mechanisms: ar-turmerone is a main component of turmeric oil with anti-inflammatory activity in cultured microglia; both S- and R-enantiomers of ar-turmerone reversed dopaminergic neurodegeneration triggered by microglial activation in midbrain slice cultures, and unexpectedly this neuroprotection was independent of the inhibition of microglial activation. An investigation using dopaminergic neuronal precursor cells suggested the possible involvement of nuclear factor erythroid 2-related factor 2 (Nrf2) in this neuroprotection.

5.5 Anticancer Mechanisms

The root cause of apoptosis induced by ar-turmerone was attributed to the elicitation of intracellular reactive oxygen species (ROS) generation, which ultimately caused an increase in PUMA, Bax, Fas, and DR4 expression along with the induction of ERK and JNK activation.

The anti-angiogenic effects of ar-turmerone were evaluated in human microvascular endothelial cells, zebrafish, and Matrigel plug mouse models; ar-turmerone significantly inhibited the proliferation, tube formation, and motility of HMEC-1 cells at non-cytotoxic concentrations; it exerted anti-angiogenic activity by down-regulation of Angiopoietin-2 and Tie-2 expression in zebrafish; and it significantly inhibited blood vessel growth, confirmed by in vivo studies using the Matrigel plug mouse model.

6. Scientific Evidence by Area of Use

Note: The overwhelming majority of evidence for turmerones comes from in vitro cell-culture studies and animal (rodent, zebrafish) models. Human clinical trials specifically investigating isolated turmerones are largely absent from the published literature. Where human or clinical data exist, they pertain primarily to whole turmeric or turmeric oil preparations and are noted as such.

6.1 Neuroinflammation and Neurodegenerative Disease

In vitro and animal evidence (preliminary): Ar-turmerone impaired the Aβ-induced inflammatory response of microglial cells by inhibiting NF-κB, JNK, and p38 MAPK signaling pathways; it protected hippocampal HT-22 cells from indirect neuronal toxicity induced by activated microglial cells; these findings were suggested to provide new insights into the development of ar-turmerone as a therapeutic agent for the treatment of neurodegenerative disorders.

In an Aβ₁₋₄₂-injected mouse model, oral administration of ar-turmerone significantly improved learning and memory performance in the Morris water maze and passive avoidance tests. However, most of these findings are limited to in vitro studies using microglial or primary neuronal cultures, and there remains a lack of in vivo evidence validating its efficacy in Alzheimer's disease models.

Evidence strength: Preclinical only. No human clinical trials have been identified that specifically test isolated turmerones for neurodegenerative disease.

6.2 Neural Stem Cell Proliferation and Neuroregeneration

In vitro and animal evidence (preliminary, mechanistically interesting): Researchers exposed primary fetal rat NSCs to various concentrations of ar-turmerone, assessing cell proliferation and differentiation potential; in vivo, naïve rats were treated with a single intracerebroventricular injection of ar-turmerone; proliferative activity of endogenous NSCs was assessed using non-invasive PET imaging and the tracer [¹⁸F]-fluoro-L-thymidine, as well as ex vivo; in vitro, ar-turmerone increased dose-dependently the number of cultured NSCs because of an increase in NSC proliferation.

At certain concentrations, ar-turmerone was shown to increase NSC proliferation by up to 80%, without having any impact on cell death; the cell differentiation process also accelerated in ar-turmerone-treated cells compared to untreated control cells. Treatment of fetal neural stem cells in vitro during expansion yielded increased proliferation, while treatment during differentiation promoted an increase in the number of generated neurons.

As ar-turmerone both limits microglial activation and induces NSC proliferation, it constitutes a promising future drug candidate to support regeneration in neurologic disorders.

Evidence strength: Preclinical (in vitro and rodent in vivo). No human studies. These findings are mechanistically compelling but remain to be translated to clinical research.

6.3 Anticonvulsant / Epilepsy

Animal evidence (moderate preclinical): The anticonvulsant properties of turmeric oil and its sesquiterpenoids (ar-turmerone, α-, β-turmerone, and α-atlantone) have been demonstrated in both zebrafish and mouse models of chemically induced seizures using pentylenetetrazole (PTZ). Ar-turmerone displayed anticonvulsant properties in both acute seizure models in mice and modulated the expression patterns of two seizure-related genes (c-fos and brain-derived neurotrophic factor [BDNF]) in zebrafish; importantly, no effects on motor function and balance were observed in mice after treatment with ar-turmerone even after administering a dose 500-fold higher than the effective dose in the 6-Hz model. Quantification of its concentration in mouse brains revealed rapid absorption after i.p. administration, capacity to cross the BBB, and long-term brain residence.

In zebrafish larvae, (+)-ar-turmerone was found to modulate the expression of two genes which are related to convulsion — c-fos and brain-derived neurotrophic factor (BDNF). Regarding anticonvulsant activity, bisabolene sesquiterpenoids, including ar-, α-, β-turmerone, and α-atlantone, have displayed anticonvulsant properties in zebrafish and murine models.

Evidence strength: Preclinical (zebrafish and rodent models). No human clinical data for turmerones specifically in epilepsy. The animal data are promising but insufficient to establish clinical recommendations.

6.4 Anticancer / Antiproliferative

In vitro evidence (preliminary): The rhizome of Curcuma longa has been commonly used in Asia for treatment of different diseases including inflammatory disorders and cancers; one study evaluated anti-proliferative activities of isolated compounds (3 curcuminoids and 2 turmerones) using human cancer cell lines HepG2, MCF-7, and MDA-MB-231, and the immunomodulatory activities of turmerones (α and aromatic) were examined using human peripheral blood mononuclear cells (PBMC); results showed that α-turmerone significantly inhibited proliferation of cancer cells in a dose-dependent manner, with IC₅₀ values ranging from 11.0–41.8 μg/ml. Alpha-turmerone induced MDA-MB-231 cells to undergo apoptosis, confirmed by annexin-V and propidium iodide staining and DNA fragmentation assay.

Both α- and β-turmerones exhibited antiproliferative activities in breast cells. Yue et al. demonstrated the enhancement of antiproliferative and anti-angiogenic activities of curcumin in the presence of turmerones in human colon cancer cells and endothelial cells, respectively. The superior anti-tumor effects of turmeric extract, which contains curcumin, turmerones, and other constituents, were verified in tumor-bearing mice, indicating the potential use of turmeric for colorectal cancer adjuvant therapy.

Fractional distillation and chromatographic separation of turmeric oil gave column fractions having biological activity against the PANC-1 pancreatic cancer cell line with an EC₅₀ in the range of 23 to 33 μg/mL; these fractions were found to contain the sesquiterpenes ar-curcumene, 7-epi-zingiberene, β-sesquiphellandrene, curlone, α-turmerone, β-turmerone, and ar-turmerone; the ability of turmeric oil components to induce cell death was independent of caspase activity.

Evidence strength: In vitro cell-line studies only. No published human clinical trials investigating turmerones as standalone anticancer agents have been identified. These results are hypothesis-generating and do not establish clinical efficacy.

6.5 Anti-inflammatory in Skin Disease

Animal evidence (preliminary): Ar-turmerone is a main constituent of essential oil from Curcuma longa with strong anti-oxidant, anti-tumor, and anti-inflammatory effects; in a study investigating the effects of ar-turmerone on imiquimod-induced psoriasis-like BALB/c mice, ar-turmerone showed inhibition of the transfer of CD8+ T cells in epidermis, and reduced expression of NF-κB and COX-2 as well as phosphorylation of p38 MAPK; it also decreased TNF-α and IL-6 levels and down-regulated IL-17, IL-22, and IL-23 mRNA synthesis.

Evidence strength: Animal model only. No human clinical trials for turmerones specifically in psoriasis or other skin disorders identified.

6.6 Antifungal / Antimicrobial

The main constituent of Curcuma longa and related plants, (+)-ar-turmerone, presents antitumor, larvicide, antifungal, and anti-inflammatory activity. A number of in vitro biological activities of turmerones have been reported, including anti-inflammatory, immunomodulatory, antiproliferative, and antifungal activities.

Evidence strength: Primarily in vitro. Historically, Thai traditional medicines containing Curcuma longa have been used for the treatment of dermatophytes, with the dry powdered rhizome mixed with water and applied onto infected skin — representing ethnomedical usage rather than controlled clinical evidence.

6.7 Antiparasitic

In vitro studies have demonstrated that ar-turmerone exhibits activity against Plasmodium falciparum 3D7 (chloroquine-sensitive), with its efficacy being contingent upon the specific stage of the parasite's life cycle; notably, ar-turmerone has been shown to inhibit the transition from the ring stage to the trophozoite stage during the intraerythrocytic life cycle; the compound displays high cytotoxic specificity, suggesting its potential as a promising non-toxic candidate for antimalarial drug development. Additionally, turmerones have demonstrated a dose-dependent capacity to inhibit the growth of Leishmania amazonensis promastigotes; however, comprehensive research is essential to elucidate the mechanisms that govern their antileishmanial effects.

Evidence strength: In vitro only. No clinical trials identified.

6.8 Blood Glucose Regulation

Turmerone has been seen to act as an anti-inflammatory and antioxidant agent that could improve insulin sensitivity and regulate blood sugar levels; in one study, insulin resistance in obese mice was treated with turmerone, which increased insulin sensitivity and reduced inflammation. In vivo biological activities of turmerones demonstrated in animal models include blood glucose-lowering effects.

Evidence strength: Animal models only. No human clinical trials isolating the role of turmerones in glycemic control.

6.9 Antidepressant Effects

Turmerones have demonstrated several in vivo biological activities including anti-depressant effects in animal models. The mechanism underlying this activity has not been fully characterized in the published literature as of the most recent research reviewed.

Evidence strength: Preclinical animal data only. No human clinical trials identified for turmerones specifically.

6.10 Whole Turmeric/Turmeric Oil Clinical Evidence

While isolated turmerones lack clinical trial evidence, one randomized controlled trial investigated a turmeric oleoresin product containing both curcuminoids and essential oils (including turmerones): CURCUGEN®, an oleoresin-based turmeric extract standardized to 50% curcuminoids and inclusive of turmeric essential oils and turmeric polysaccharides, was tested in a randomized, double-blind, placebo-controlled study on middle-aged men and women with self-reported digestive complaints; CURCUGEN® effectively reduced Gastrointestinal Symptom Rating Scale (GSRS) and anxiety scores without eliciting severe or serious adverse events. This study does not allow attribution of effect specifically to turmerones.

7. Body Systems and Health Areas

Research indicates that the primary active compounds in turmeric essential oil are promising candidates for addressing a wide range of pathologies, exhibiting anticancer, anti-inflammatory, antioxidant, cardiovascular, hypoglycemic, dermatological, hepatoprotective, neurological, antiparasitic, antiviral, insecticidal, antifungal, and antivenom activities. In vitro studies have reported turmerone effects on several biological activities, including anti-inflammatory, anti-immunomodulatory, anti-proliferative activity for cultured cancer cells, antifungal activities, and inhibitory effects on β-secretase.

The body systems and health areas with which turmerones have been associated, based on available preclinical evidence, are as follows:

Central nervous system: Neuroinflammation suppression; neural stem cell proliferation and neurogenesis; anticonvulsant activity; neuroprotection in models of Alzheimer's and Parkinson's disease; blood–brain barrier penetration documented in animal models.
Immune system: Modulation of T-cell activity; microglial activation control; cytokine regulation (TNF-α, IL-1β, IL-6, IL-17, IL-22, IL-23); dendritic cell maturation.
Oncology: Antiproliferative and pro-apoptotic activity in multiple cancer cell lines; anti-angiogenic properties; enhancement of curcumin's antiproliferative action.
Skin: Antifungal/antidermatophytic activity; anti-inflammatory effects in psoriasis models; traditional antiseptic use.
Metabolic/endocrine: Blood glucose modulation; improvement of insulin sensitivity in obese animal models.
Gastrointestinal: Carminative properties (traditional); modulation of curcumin absorption via P-gp inhibition.
Infectious disease: Antiplasmodial (anti-malarial), antileishmanial, and antifungal activities in vitro.
Mood/psychiatry: Antidepressant activity reported in animal models.

8. Dosage Forms and Doses Reported in Studies

Because no approved dosage regimen exists for isolated turmerones as a supplement, the following reflects doses and forms described specifically in published research:

Oral administration in mice (antioxidant/antinociceptive): Oral administration of 500 mg/kg turmeric essential oil increased levels of the antioxidant enzymes superoxide dismutase, glutathione reductase, and glutathione-S-transferase in mice.
Anticonvulsant study (mice, i.p. route): No effects on motor function and balance were observed in mice after treatment with ar-turmerone even after administering a dose 500-fold higher than the effective dose in the 6-Hz model. The specific effective anticonvulsant dose was evaluated in the i.v. PTZ and 6-Hz mouse models.
Neural stem cell study (intracerebroventricular, rats): Naïve rats were treated with a single intracerebroventricular injection of ar-turmerone to assess endogenous NSC proliferation.
In vitro antiproliferative (cancer cell lines): α-Turmerone significantly inhibited proliferation of cancer cells (HepG2, MCF-7, MDA-MB-231) in a dose-dependent manner; IC₅₀ values of these compounds in cancer cells ranged from 11.0–41.8 μg/mL.
Pancreatic cancer cell line (in vitro): Turmeric oil column fractions had biological activity against the PANC-1 pancreatic cancer cell line, with an EC₅₀ in the range of 23 to 33 μg/mL.
Neuroinflammation in vitro: Ar-turmerone was tested at concentrations of 0–20 μM in microglial cell cultures over a 28-hour period to assess suppression of inflammatory markers.
Bioavailability enhancement (animal, ar-turmerone co-administered with curcuminoids): Animals fed with curcuminoid mixture blended with essential oil of turmeric having 45% or 50% ar-turmerone showed approximately 10.9-fold and 10.8-fold enhanced curcumin bioavailability, respectively, compared to regular turmeric extract.
Administration by inhalation (mice): Inhaled turmerones were incorporated in the organs via pathways different from oral administration and could affect weight gain of mice in a 2022 Scientific Reports study, though specific inhaled doses were not extractable from available data.

No established human clinical doses for purified or isolated turmerones have been identified in the peer-reviewed literature reviewed for this article.

9. Safety Considerations

9.1 General Toxicological Profile

Toxicological studies on turmeric essential oil indicate no genotoxicity or dermal toxicity, minimal systemic toxicity, and good tolerability in humans; the pharmacology data supports anti-inflammatory, antimicrobial, neuroprotective, antioxidant, and anticancer properties, with synergistic effects when turmerones and curcuminoids are combined; turmeric rhizome essential oil has demonstrated a favorable safety profile and diverse bioactivities with therapeutic potential.

Turmeric essential oil exhibits a favorable safety profile when consumed in dietary contexts, with no documented cases of toxicity associated with its oral intake; the cytotoxic effects observed in laboratory settings are context-specific and dose-dependent.

In animal anticonvulsant safety testing, no effects on motor function and balance were observed in mice after treatment with ar-turmerone even after administering a dose 500-fold higher than the effective dose in the 6-Hz model.

9.2 Regulatory Status

In Europe, turmeric and its essential oil have been listed among botanicals allowed to be used in food supplements; turmeric and curcumin are also listed by the FDA among the GRAS substances for use as a dye and flavoring in food. These designations apply to turmeric as a whole food ingredient; the regulatory status of isolated turmerones as standalone dietary supplement ingredients is not separately defined in these sources.

9.3 P-glycoprotein Interactions

A significant, source-verified pharmacological interaction relevant to safety is the P-gp inhibitory activity of turmerones. α-Turmerone significantly inhibited the activity of P-glycoprotein, with effects comparable to the known P-gp inhibitor verapamil. P-gp is a major efflux transporter that controls the intestinal absorption and tissue distribution of many pharmaceutical drugs (including digoxin, certain chemotherapy agents, and immunosuppressants). Inhibition of P-gp by turmerones could theoretically increase plasma levels of co-administered P-gp substrates, though this has been demonstrated in intestinal cell culture (Caco-2) and has not been characterized in clinical pharmacokinetic studies in humans.

9.4 Product Quality and Adulteration

Most market samples of turmeric essential oil exhibit the large dominance of turmerones, but some show compositional variability, dilution, or adulteration — including 4/25 samples containing adulteration markers — highlighting the need for production standards. Consumers using turmerone-containing products should be aware of this variability, which may affect both efficacy and safety of commercial preparations.

9.5 Absence of Human Clinical Safety Data for Isolated Turmerones

No published clinical trials have specifically evaluated the safety of isolated turmerone fractions in humans at supplemental or therapeutic doses. All safety characterization available derives from animal studies, in vitro data, and the GRAS/food-additive status of the whole turmeric plant. The mechanisms by which ar-turmerone operates and its safety in humans require additional exploration.

10. Summary of Evidence Quality

Turmerones represent a chemically distinct and pharmacologically active component of turmeric essential oil that has received substantially less research attention than curcumin. Most pharmacological activities of turmeric have been explained by the properties of curcumin, mainly because turmeric oil has not been as extensively studied as curcuminoids. However, curcumin-free extracts and preparations have been reported biologically active on different diseases such as tumors and diabetes.

The current state of evidence can be summarized as follows: there is a substantial body of in vitro and animal data supporting anti-inflammatory, neuroprotective, anticonvulsant, anticancer, antifungal, and antiparasitic activities; the mechanistic data are detailed and internally consistent across multiple independent research groups; the neural stem cell proliferation findings in rodents represent an especially distinctive and well-documented activity; and the curcumin bioavailability-enhancing mechanism via P-gp inhibition has been replicated in human cell models. However, the absence of human clinical trials testing isolated turmerones means that efficacy and optimal dosing in humans have not been established for any indication. Pharmacology data supports anti-inflammatory, antimicrobial, neuroprotective, antioxidant, and anticancer properties, with synergistic effects when turmerones and curcuminoids are combined.

References

Health Conditions

Health conditions that Turmerones may help support.

No conditions available.

Body Systems

Body systems that Turmerones may help support.

No body systems available.